\BOOKMARK [0][-]{section*.4}{Glossary}{}% 1
\BOOKMARK [0][-]{section*.6}{Acronyms}{}% 2
\BOOKMARK [0][-]{chapter.1}{Introduction and Literature Review}{}% 3
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 4
\BOOKMARK [2][-]{subsection.1.1.1}{Cancer is a Global Health Issue}{section.1.1}% 5
\BOOKMARK [3][-]{subsubsection.1.1.1.1}{The Genetics and Molecular Biology of Cancers}{subsection.1.1.1}% 6
\BOOKMARK [2][-]{subsection.1.1.2}{The Genomics Revolution in Cancer Research}{section.1.1}% 7
\BOOKMARK [3][-]{subsubsection.1.1.2.1}{Sequencing and Genotyping Technologies}{subsection.1.1.2}% 8
\BOOKMARK [3][-]{subsubsection.1.1.2.2}{Microarrays and Quantitative Technologies}{subsection.1.1.2}% 9
\BOOKMARK [3][-]{subsubsection.1.1.2.3}{Massively Parallel ``Next Generation'' Sequencing}{subsection.1.1.2}% 10
\BOOKMARK [4][-]{subsubsubsection.1.1.2.3.1}{Molecular Profiling with Genomics Technology}{subsubsection.1.1.2.3}% 11
\BOOKMARK [4][-]{subsubsubsection.1.1.2.3.2}{Sequencing Technologies}{subsubsection.1.1.2.3}% 12
\BOOKMARK [3][-]{subsubsection.1.1.2.4}{Genomic Data Analysis and Bioinformatics}{subsection.1.1.2}% 13
\BOOKMARK [2][-]{subsection.1.1.3}{Genomics Projects}{section.1.1}% 14
\BOOKMARK [3][-]{subsubsection.1.1.3.1}{The Cancer Genome Project}{subsection.1.1.3}% 15
\BOOKMARK [3][-]{subsubsection.1.1.3.2}{The Cancer Genome Atlas Project}{subsection.1.1.3}% 16
\BOOKMARK [4][-]{subsubsubsection.1.1.3.2.1}{Findings from Cancer Genomes}{subsubsection.1.1.3.2}% 17
\BOOKMARK [4][-]{subsubsubsection.1.1.3.2.2}{Genomic Comparisons across Cancer Tissues}{subsubsection.1.1.3.2}% 18
\BOOKMARK [4][-]{subsubsubsection.1.1.3.2.3}{Cancer Genomic Data Resources}{subsubsection.1.1.3.2}% 19
\BOOKMARK [2][-]{subsection.1.1.4}{Genomic Cancer Medicine}{section.1.1}% 20
\BOOKMARK [3][-]{subsubsection.1.1.4.1}{Cancer Genes and Driver Mutations}{subsection.1.1.4}% 21
\BOOKMARK [3][-]{subsubsection.1.1.4.2}{Personalised or Precision Cancer Medicine}{subsection.1.1.4}% 22
\BOOKMARK [4][-]{subsubsubsection.1.1.4.2.1}{Molecular Diagnostics and Pan-Cancer Medicine}{subsubsection.1.1.4.2}% 23
\BOOKMARK [3][-]{subsubsection.1.1.4.3}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.4}% 24
\BOOKMARK [4][-]{subsubsubsection.1.1.4.3.1}{Targeting Oncogenic Driver Mutations}{subsubsection.1.1.4.3}% 25
\BOOKMARK [3][-]{subsubsection.1.1.4.4}{Systems and Network Biology}{subsection.1.1.4}% 26
\BOOKMARK [4][-]{subsubsubsection.1.1.4.4.1}{Network Medicine, and Polypharmacology}{subsubsection.1.1.4.4}% 27
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 28
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 29
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 30
\BOOKMARK [2][-]{subsection.1.2.3}{Studies of Synthetic Lethality}{section.1.2}% 31
\BOOKMARK [3][-]{subsubsection.1.2.3.1}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 32
\BOOKMARK [4][-]{subsubsubsection.1.2.3.1.1}{Evolution of Synthetic Lethality}{subsubsection.1.2.3.1}% 33
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethal Concepts in Cancer}{section.1.2}% 34
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 35
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 36
\BOOKMARK [3][-]{subsubsection.1.2.6.1}{Synthetic Lethal Screens}{subsection.1.2.6}% 37
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 38
\BOOKMARK [3][-]{subsubsection.1.2.7.1}{Bioinformatics Approaches to Genetic Interactions}{subsection.1.2.7}% 39
\BOOKMARK [3][-]{subsubsection.1.2.7.2}{Comparative Genomics}{subsection.1.2.7}% 40
\BOOKMARK [3][-]{subsubsection.1.2.7.3}{Analysis and Modelling of Protein Data}{subsection.1.2.7}% 41
\BOOKMARK [3][-]{subsubsection.1.2.7.4}{Differential Gene Expression}{subsection.1.2.7}% 42
\BOOKMARK [3][-]{subsubsection.1.2.7.5}{Data Mining and Machine Learning}{subsection.1.2.7}% 43
\BOOKMARK [3][-]{subsubsection.1.2.7.6}{Bimodality}{subsection.1.2.7}% 44
\BOOKMARK [3][-]{subsubsection.1.2.7.7}{Rationale for Further Development}{subsection.1.2.7}% 45
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 46
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and its Biological Functions}{section.1.3}% 47
\BOOKMARK [3][-]{subsubsection.1.3.1.1}{Cytoskeleton}{subsection.1.3.1}% 48
\BOOKMARK [3][-]{subsubsection.1.3.1.2}{Extracellular and Tumour Micro-environment}{subsection.1.3.1}% 49
\BOOKMARK [3][-]{subsubsection.1.3.1.3}{Cell-Cell Adhesion and Signalling}{subsection.1.3.1}% 50
\BOOKMARK [2][-]{subsection.1.3.2}{CDH1 as a Tumour \(and Invasion\) Suppressor}{section.1.3}% 51
\BOOKMARK [3][-]{subsubsection.1.3.2.1}{Breast Cancers and Invasion}{subsection.1.3.2}% 52
\BOOKMARK [2][-]{subsection.1.3.3}{Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{section.1.3}% 53
\BOOKMARK [2][-]{subsection.1.3.4}{Models of CDH1 loss in cell lines}{section.1.3}% 54
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 55
\BOOKMARK [2][-]{subsection.1.4.1}{Thesis Aims}{section.1.4}% 56
\BOOKMARK [0][-]{subsection.1.4.1}{References}{}% 190
